Abstract: Processes for the preparation of certain 5,7-diaminopyrazolo[1,5-?]pyrimidine compounds comprising the reaction of a primary or secondary amine and a protected 5-halo-7-aminopyrazolo[1,5-?]pyrimidine compound in solvent system comprising water and one or more organic solvents, optionally in the presence of an exogenous base.
Type:
Grant
Filed:
June 9, 2011
Date of Patent:
August 13, 2013
Assignees:
Emory University, Imperial College of Science and Technology
Inventors:
Dennis C. Liotta, James P. Snyder, Ashutosh S. Jogalekar, Anthony G. M. Barrett, Matthew John Fuchter, Matthew J. Cook, Sebastian H. B. Kroll
Abstract: This invention provides a class of compounds which are useful for specifically inhibiting cyclin-dependent kinases. This class of compounds finds use in treating diseases resulting from inappropriate activity of cyclin-dependent kinases, including cancer, viral infections (e.g., HIV) neurodegenerative disorders (e.g. Alzheimer's disease), and cardiovascular disorders (e.g. atherosclerosis). Moreover, certain members of this class are particularly useful for inhibiting cyclin-dependent kinase 7 and are especially useful for the treatment of breast cancer.
Type:
Grant
Filed:
December 4, 2009
Date of Patent:
November 29, 2011
Assignees:
Emory University, Imperial College of Science and Technology
Inventors:
Ashutosh S. Jogalekar, James P. Snyder, Dennis C. Liotta, Anthony G. M. Barrett, Raoul Charles Dalmedo Stuart Coombes, Simak Ali, Aleksandra Siwicka, Jan Brackow, Bodo Scheiper
Abstract: Methods and compositions for modulating neurite outgrowth in damaged neural endplates. Also disclosed are methods for introducing drugs, ribozymes, antisense oligonucleotides and defective receptor genes within neurons.
Type:
Application
Filed:
September 18, 2003
Publication date:
November 18, 2004
Applicants:
Allergan, Inc., Imperial College of Science and Technology
Inventors:
Dolly J. Oliver, Kei Roger Aoki, Anton De Paiva
Abstract: Individual subtypes of interferon-.alpha. (IFN-.alpha.) have been found to have different antiviral activity in different cell types and are therefore used to prevent or treat viral infections in cell types in which they are most active. The individual subtype of choice has relatively low antiviral activity in other celltypes to reduce the risk of side effects. IFN-.alpha..sub.10 and/or IFN-.alpha..sub.17 are preferred for use in treating viral lung infections and IFN-.alpha..sub.8 is preferred for use in treating viral liver infections.
Type:
Grant
Filed:
September 24, 1996
Date of Patent:
December 28, 1999
Assignee:
Imperial College of Science and Technology
Inventors:
Graham Russell Foster, Howard Christopher Thomas
Abstract: An artificial ligament for connecting across a skeletal joint comprises a bundle of fibers 1 each comprising a plurality of filaments 1a of polyethylene terephthalate. The ligament is constructed by winding a plurality of turns of the fiber 1 onto a winding apparatus and then binding the ends to form loops 4.Also disclosed is a ligament fixation device in the form of a cylindrical grommet, and a tensioning instrument for use in implanting an artificial ligament.
Type:
Grant
Filed:
November 28, 1994
Date of Patent:
November 19, 1996
Assignee:
Imperial College of Science and Technology